Clinical Trial Update: A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of VX-445 (elexacaftor) in healthy subjects and cystic fibrosis patients completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-445

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-01-18